LOGIN
ID
PW
MemberShip
2025-07-03 14:19
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Lilly launches Ebglyss in Korea¡¦ sparks competition
by
Son, Hyung Min
Jul 3, 2025 06:12am
The official launch of Lilly's Ebglyss has expanded treatment options for atopic dermatitis patients in Korea. With the arrival of Ebglyss, the number of biological agents available for the treatment of atopic dermatitis in Korea has increased to three. Experts welcomed the emergence of diverse treatment options but emphasized that there i
Company
Will twice-yearly Bayer's 'Eylea' become available in KOR?
by
Eo, Yun-Ho
Jul 3, 2025 06:12am
Twice-yearly administration of 'Eylea,' used to treat eye disease, is anticipated to be possible in South Korea. The Ministry of Food and Drug Safety (MFDS) is conducting a review of the expanded indication for the administration of Bayer Korea's high-dose Eylea (aflibercept) 8 mg at intervals of up to 6-months. The approval is expected i
Company
Pharma tries to flip the returned out-licensing of new drugs
by
Son, Hyung Min
Jul 3, 2025 06:11am
New drug candidates from Korean pharmaceutical companies, which were previously returned after technology transfer, are now re-entering the clinical stage and proving their potential. Attention is focused on whether these candidates will re-label their past failures and demonstrate technological potential. According to industry sources on Jul
Company
SK Bioscience invests billions in the post-pandemic era
by
Chon, Seung-Hyun
Jul 3, 2025 06:10am
SK Bioscience has taken proactive steps to discover new growth engines in preparation for the post-pandemic era. The company has invested KRW 81.5 billion to expand its vaccine plant in Andong and approximately KRW 300 billion for the acquisition of a German CDMO biotech company. The construction of its headquarters, research center, and factory
Company
AbbVie Korea launches new glaucoma treatment 'XEN 63'
by
Whang, byung-woo
Jul 3, 2025 06:08am
AbbVie Korea announced on July 1 that it has launched XEN 63, a new option for glaucoma treatment in patients whose intraocular pressure (IOP) is not controlled by previous glaucoma surgery or existing medicines. With the expansion of the XEN Gel Implant portfolio, including XEN 45, patients now have a wider range of personalized treatment
Company
Leclaza combination therapy takes over Europe
by
Moon, sung-ho
Jul 3, 2025 06:07am
Leclaza (lazertinib), a new lung cancer drug developed by Yuhan Corporation, has been officially included in the European Society for Medical Oncology (ESMO) guidelines. Reflecting the latest clinical study findings, Leclaza in combination with Rybrevant (amivantamab, Johnson & Johnson) has been included as a first-line option in the guidelin
Company
¡®TNF-¥á inhibitors, a cornerstone for rheumatoid arthritis'
by
Whang, byung-woo
Jul 2, 2025 06:09am
Rheumatoid arthritis is a chronic autoimmune condition that causes inflammation in the joints, leading to pain and deformity. Its prevalence in Korea is estimated to be approximately 0.5&8211;1% Recently, with the development of new treatments and improved awareness of the disease, early diagnosis rates are on the rise. In fact, over the
Company
K-CAB¡¤Entresto awaiting the Supreme Court rulings
by
Kim, Jin-Gu
Jul 2, 2025 06:09am
Patent disputes involving blockbuster drugs, K-CAB (tegoprazan) and Entresto (valsartan/sacubitril), are reaching their final stages. Observations suggest that the Supreme Court's final ruling could come as early as the second half of this year. K-CAB's annual prescription sales amount to KRW 200 billion, while Entresto's are KRW 70 billion.
Company
Generics of Jardiance expected to compete for KRW 100B mkt
by
Kim, Jin-Gu
Jul 2, 2025 06:08am
The substance patent for Jardiance (empagliflozin), a diabetes treatment generating annual sales of approximately KRW 100 billion, is set to expire this October. Generic competition in the SGLT-2 inhibitor diabetes drug market is likely to heat up again. Approximately 50 companies have already secured approvals for related generic products
Company
Asthma drug 'Trelegy 200 Ellipta Inhaler' becomes available
by
Eo, Yun-Ho
Jul 1, 2025 06:03am
The asthma treatment 'Trelegy 200 Ellipta Inhaler' is now available for prescription at tertiary general hospitals. According to industry sources, Trelegy 200 Ellipta Inhaler (fluticasone furoate¡¤umeclidinium¡¤vilanterol) has passed the drug committees (DC) of Korea's 'Big 5' tertiary general hospitals, including Samsung Medical Center,
1
2
3
4
5
6
7
8
9
10
>